Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

NCT04152863 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Advanced/Metastatic Melanoma

Interventions

BIOLOGICAL: Gebasaxturev IV
BIOLOGICAL: Gebasaxturev ITu
DRUG: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC